Aardvark Therapeutics (AARD) Other Non-Current Liabilities (2024 - 2025)

Aardvark Therapeutics (AARD) posted Other Non-Current Liabilities of $12000.0 for Q2 2025, down 50.0% sequentially from $24000.0 in Q1 2025.

Aardvark Therapeutics (AARD) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends

Aardvark Therapeutics has reported Other Non-Current Liabilities for 2 years, with the latest figure at $12000.0 in Q2 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $12000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $12000.0 (changed N/A YoY) and the FY2024 annual result came in at $26000.0, changed N/A from the prior year.
Other Non-Current Liabilities retreated to $12000.0 in Q2 2025 per AARD's latest filing, from $24000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $26000.0 in Q4 2024 and troughed at $12000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Aardvark Therapeutics	147.46 Mn	73.54 Mn	-

Download Data